Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (271-280 of 713) with videos related to

Pageof 72
Sort By:
Experimental Hematology|May 30, 2007
Imatinib effect on growth and signal transduction in polycythemia veraAmos Gaikwad, Srdan Verstovsek, Donghoon Yoon, et al.
Cancer|July 9, 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemiaCarlos E Bueso-Ramos, Jorge Cortes, Moshe Talpaz, et al.
Leukemia Research|June 12, 2017
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosisLucia Masarova, Prithviraj Bose, Naval Daver, et al.
Leukemia & Lymphoma|January 19, 2010
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remissionHagop M Kantarjian, Deborah Thomas, Farhad Ravandi, et al.
Haematologica|February 14, 2007
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemiaWanlong Ma, Richard Tseng, Mercedes Gorre, et al.
Haematologica|February 9, 2012
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialFrançois Guilhot, Timothy P Hughes, Jorge Cortes, et al.
Leukemia Research|January 18, 2003
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemiaEfrosyni Apostolidou, Elihu Estey, Jorge Cortes, et al.
Cancer|October 30, 2003
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseJorge Medina, Hagop Kantarjian, Moshe Talpaz, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phaseFabio P S Santos, Hagop Kantarjian, David McConkey, et al.
Molecular Cancer Therapeutics|September 3, 2009
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cellsDuncan H Mak, Wendy D Schober, Wenjing Chen, et al.
Pageof 72

Showing results (271-280 of 713) with videos related to

Sort By:
Pageof 72
Experimental Hematology|May 30, 2007
Imatinib effect on growth and signal transduction in polycythemia veraAmos Gaikwad, Srdan Verstovsek, Donghoon Yoon, et al.
Cancer|July 9, 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemiaCarlos E Bueso-Ramos, Jorge Cortes, Moshe Talpaz, et al.
Leukemia Research|June 12, 2017
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosisLucia Masarova, Prithviraj Bose, Naval Daver, et al.
Leukemia & Lymphoma|January 19, 2010
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remissionHagop M Kantarjian, Deborah Thomas, Farhad Ravandi, et al.
Haematologica|February 14, 2007
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemiaWanlong Ma, Richard Tseng, Mercedes Gorre, et al.
Haematologica|February 9, 2012
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialFrançois Guilhot, Timothy P Hughes, Jorge Cortes, et al.
Leukemia Research|January 18, 2003
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemiaEfrosyni Apostolidou, Elihu Estey, Jorge Cortes, et al.
Cancer|October 30, 2003
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phaseJorge Medina, Hagop Kantarjian, Moshe Talpaz, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phaseFabio P S Santos, Hagop Kantarjian, David McConkey, et al.
Molecular Cancer Therapeutics|September 3, 2009
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cellsDuncan H Mak, Wendy D Schober, Wenjing Chen, et al.
Pageof 72